Uncertainty over the payments that will be due from companies to manage the branded medicines bill in 2023 and beyond has been a cause for concern for firms, which last month had to decide whether to remain in or exit the Voluntary Scheme for Branded Medicines Pricing and Access. If many companies have left, the “remainers” might end up paying more than their fair share, though the government has offered some assurance on this front.
Companies whose revenues in the UK are shaped by the government’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which will end next year, faced a difficult decision last month.
They had to choose by 30 September whether to stay in the scheme and potentially risk having to pay the bill left by those who opted to leave and enter...